Viridian Therapeutics, Inc.\DE (VRDN) Debt to Equity: 2014-2025
Historic Debt to Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Sep 2025 value amounting to $0.04.
- Viridian Therapeutics, Inc.\DE's Debt to Equity rose 43.18% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.04, marking a year-over-year increase of 43.18%. This contributed to the annual value of $0.03 for FY2024, which is 32.96% down from last year.
- Viridian Therapeutics, Inc.\DE's Debt to Equity amounted to $0.04 in Q3 2025, which was up 2.93% from $0.04 recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's Debt to Equity registered a high of $0.05 during Q4 2023, and its lowest value of $0.03 during Q3 2024.
- Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Debt to Equity value was $0.04 (recorded in 2024), while the average stood at $0.04.
- Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Debt to Equity tumbled by 32.96% in 2024 and then surged by 43.18% in 2025.
- Quarterly analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Debt to Equity stood at $0.05 in 2023, then plummeted by 32.96% to $0.03 in 2024, then surged by 43.18% to $0.04 in 2025.
- Its Debt to Equity was $0.04 in Q3 2025, compared to $0.04 in Q2 2025 and $0.03 in Q1 2025.